Navigation Links
New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia

ession, and depression. Efficacy was assessed from the change from baseline to study endpoint (Day 42) using PANSS total score as well as positive symptom, negative symptom, general psychopathology, aggression, and depression rating scores.(2)

At Day 42, there were statistically significant reductions versus placebo with all doses of SEROQUEL XR for the change in PANSS total, positive subscale, general psychopathology subscale, and hostility and aggression scores. Changes in negative symptom and depression scores of the PANSS were statistically significant versus placebo for SEROQUEL XR 600 mg/day and 800 mg/day.(2)

IMPORTANT SAFETY INFORMATION FOR SEROQUEL XR

SEROQUEL XR is indicated for the treatment of schizophrenia. Patients should be periodically reassessed to determine the need for treatment beyond the acute response.

Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk (1.6 to 1.7 times) of death compared to placebo (4.5% vs 2.6%, respectively). SEROQUEL XR is not approved for the treatment of patients with dementia-related psychosis. (See Boxed Warning.)

Hyperglycemia, in some cases extreme and associated with ketoacidosis, hyperosmolar coma, or death, has been reported in patients treated with atypical antipsychotics, including quetiapine. The relationship of atypical use and glucose abnormalities is complicated by the possibility of increased risk of diabetes in the schizophrenic population and the increasing incidence of diabetes in the general population. However, epidemiological studies suggest an increased risk of treatment-emergent, hyperglycemia-related adverse events in patients treated with atypical antipsychotics. Patients starting treatment with atypical antipsychotics who have or are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and during treatment. Patients who develop symptoms of hyperglycemia should also u
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:8/27/2014)... DANVERS, Mass. , Aug. 27, 2014 North ... with a prestigious R&D 100 Award for the new OSRAM ... laser and LED-based white light module for microscopy, endoscopy and ... Xenon lamps with significantly higher efficacy and lamp life. ... as one of the most innovative new technologies of ...
(Date:8/27/2014)... Aug. 27, 2014  Columbia Laboratories, Inc. (Nasdaq: ... of pharmaceutical development, clinical trial manufacturing, and advanced analytical ... that it will participate at the upcoming Rodman & ... be held in New York . ... on September 9, 2014 at the New York Palace ...
(Date:8/27/2014)... 27, 2014 /CNW/ - Covalon Technologies Ltd. (the "Company" or ... following financial results for its third quarter of fiscal 2014: ... , Revenue of $1,291,378, a 13% decrease over ... loss for the quarter of $240,156 compared to net income ... For the nine months ended June 30, ...
Breaking Medicine Technology:OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 2OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 3Covalon Announces Third Quarter Results 2Covalon Announces Third Quarter Results 3
... Medicaid and the State of Alabama are partnering with ... infrastructure for a statewide health information exchange (HIE) that ... (Logo: http://photos.prnewswire.com/prnh/20090507/NY12658LOGO) The partnership is ... diverse group of stakeholders into functional, user-friendly design for ...
... /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTCBB: LTUS) ("Lotus" ... medicine and drugs in the People,s Republic of China ("PRC"), ... ended September 30, 2011. Summary financial data is provided below: ... Financial Highlights Revenues for the ...
Cached Medicine Technology:Alabama Selects Thomson Reuters HIE Advantage™ for Statewide Health Information Exchange 2Alabama Selects Thomson Reuters HIE Advantage™ for Statewide Health Information Exchange 3Lotus Pharmaceuticals Announces Third Quarter 2011 Financial Results 2Lotus Pharmaceuticals Announces Third Quarter 2011 Financial Results 3Lotus Pharmaceuticals Announces Third Quarter 2011 Financial Results 4Lotus Pharmaceuticals Announces Third Quarter 2011 Financial Results 5Lotus Pharmaceuticals Announces Third Quarter 2011 Financial Results 6
(Date:8/27/2014)... Silver Spring, Md. (PRWEB) August 27, 2014 ... Physicians (CHEST) recently released guidelines for the management ... adults, Pharmacological Therapy for Pulmonary Arterial Hypertension in ... guidelines are free to view for clinicians, and ... for PAH. , The Pulmonary Hypertension Association ...
(Date:8/27/2014)... Dennis Thompson HealthDay ... Someone who has been mugged in a dark alley will ... with a fear of being attacked. But neuroscientists working ... how memories are linked with positive and negative emotions. And ... emotions attached to a memory. In essence, they made ...
(Date:8/27/2014)... Warren, MI (PRWEB) August 27, 2014 Michigan ... to help the children of a local elementary school by ... year. Siersma Elementary School has year-round attendance, and Michigan Head ... equipped to meet the new school year. , "There are ... think this is a great way to give back to ...
(Date:8/27/2014)... August 27, 2014 The federal judge ... ) has extended the deadline for plaintiffs to enroll ... 2014 Order issued by U.S. District Judge David Katz ... enroll in the DePuy ASR Settlement Program must do ... Inc. ASR Hip Implant Products Liability Litigation – MDL ...
(Date:8/27/2014)... (HealthDay News) -- Pouring half a glass of wine at a ... new study. Researchers asked 74 college students and staff to ... that had varying amounts of wine in them. The participants were ... had a "rule of thumb" about how much to pour -- ... from the top -- poured less wine than those without set ...
Breaking Medicine News(10 mins):Health News:Pulmonary Hypertension Association Endorses CHEST Guidelines for Treatment of Pulmonary Arterial Hypertension in Adults 2Health News:Scientists 'Rewrite' Bad Memories in Mice 2Health News:Scientists 'Rewrite' Bad Memories in Mice 3Health News:Michigan Head & Neck Institute is Conducting Their 2nd Annual School Supplies Drive at Their Facility to Benefit Local Year-Round Elementary School Students 2Health News:DePuy ASR Settlement Enrollment Deadline Extended Until September 30, 2014, Bernstein Liebhard LLP Reports 2Health News:DePuy ASR Settlement Enrollment Deadline Extended Until September 30, 2014, Bernstein Liebhard LLP Reports 3Health News:'Half a Glass' Rule May Curb Overdrinking 2
... Mismatch occurs between seeing letter and the sound it ... -- New brain scans reveal more about how the ... problem seems to be a mismatch between seeing the ... or vice-versa, said researchers from the University of Maastricht ...
... to heart attacks than their predecessors, researchers say , , THURSDAY, ... good shape, even when compared with their counterparts 10 or ... study, more aging boomers are being hospitalized for heart attacks ... the increase in cases could place a big burden on ...
... Shamir Optical Industry Ltd. (Nasdaq: SHMR ) ("Shamir") ... earnings results on Wednesday, March 18, 2009, and has scheduled ... EDT that morning. The conference call will be broadcast live ... www.kcsa.com approximately five minutes before the conference call ...
... MESSA,s East Lansing-based ... consecutive year for superior efficiency and performance in providing ... providing efficient and effective customer service as measured against ... at Purdue University and BenchmarkPortal. "MESSA is ...
... Care Management Software Applications As Part of Electronic ... TCS Healthcare Technologies (TCS), an industry ... applications, supports the health information technology (IT) provisions ... as the American Recovery and Reinvestment Act of ...
... researchers find aerosol levels have diminished visibility , , THURSDAY, ... of data showing how clear, or unclear, the sky ... air pollution have affected climate change, according to a ... show that what the researchers call clear sky visibility ...
Cached Medicine News:Health News:Brain Scans Shed Light on Dyslexia 2Health News:Brain Scans Shed Light on Dyslexia 3Health News:Aging Baby Boomers May Swamp Cardiac Care 2Health News:Aging Baby Boomers May Swamp Cardiac Care 3Health News:Shamir Optical Industry Ltd. to Host Conference Call Announcing Fourth Quarter and Year End 2008 Earnings Results 2Health News:MESSA Receives National Recognition for Best Practices in Providing Efficient, Cost-Effective Customer Service 2Health News:MESSA Receives National Recognition for Best Practices in Providing Efficient, Cost-Effective Customer Service 3Health News:TCS Healthcare Technologies Offers Health IT Solutions That Support Health Care Reform 2Health News:TCS Healthcare Technologies Offers Health IT Solutions That Support Health Care Reform 3Health News:Clear Skies Have Become Less So Over Time, Data Show 2
The Fluoroskan Ascent, a dedicated microplate fluorometer, offers high sensitivity for a wide variety of fluorometric applications....
The VersaFluor cuvette fluorometer is a fast and simple way to quantitate DNA, RNA, and proteins, to detect apoptosis, and to perform reporter enzyme assays with the high level of sensitivity and sel...
... unique microprocessor-controlled filter wheels for wavelength selection ... filter wheels can be programmed for excitation ... With this fluorometer, you do not have ... wavelengths. The C&L Dye Fluorometer can measure ...
The TBS-380 Fluorometer is an economical, sensitive fluorometer designed for quick, easy, and accurate fluorescent measurements....
Medicine Products: